UNSPSC 51112013: Dasatinib hydrate

This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H26ClN7O2S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RBZ1571X5H, chemically known as 5-thiazolecarboxamide, n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)- but more generally known as dasatinib, which bears US NIH Compound Identifier 3062316. European Medicines Agency schedules Dasatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23322.

World Health Organization schedules dasatinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule dasatinib hydrate under HS 29341000. SMILES: CC1CCCC(C1NC(=O)C2CNC(S2)NC3CC(NC(N3)C)N4CCN(CC4)CCO)CL.O.

UNSPSC 51112013 Dasatinib hydrate is a Commodity code covering specific pharmaceutical active ingredients supplied through state and local government cooperative purchasing agreements. State and local procurement under this code centers on establishing blanket supply contracts for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to government health facilities, prisons, mental health systems, and other state and local agencies. The work involves manufacturers or authorized distributors providing FDA-compliant pharmaceutical products with certified pricing, compliance documentation (including cGMP and Drug Supply Chain Security Act certification), and ability to maintain relationships with multiple authorized wholesalers. Issuing bodies include state health and human services departments, departments of administration, multistate cooperative purchasing alliances, and county and local health authorities that participate in collaborative procurement vehicles.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local facilities across Minnesota and Oregon. The MMCAP solicitation requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), submit pricing in multiple formats (flat price, net price NF30/NF60/NF90, or WAC-minus), maintain $5 million commercial general liability insurance and $2 million network security and professional liability coverage, and demonstrate EDI capability. Award is weighted primarily on price competitiveness (75 percent), with vendor compliance with administrative formats, EDI, and fixed pricing evaluated at lower weights. The contract term runs two years for new vendors with optional MMCAP extensions, and all products must be available in the marketplace by May 15, 2026, with contract performance effective July 1, 2026.